Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.

Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial.

For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy.

Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.

Metastatic Breast Cancer Trial - Y2301

The purpose of this phase III study is to compare efficacy and safety of a Novartis investigational drug along with an additional therapy in treating postmenopausal women with estrogen receptor positive (ER+) locally advanced or metastatic breast cancer refractory to nonsteroidal aromatase inhibitors (NAI). An "investigational drug" is a drug that is being clinically tested and is not approved for sale or use in the United States by the Food and Drug Administration (FDA), for the indication in which it is being studied.

HER2 Positive Breast Cancer Trial - J2301

The purpose of this randomized, phase III, double-blind, placebo-controlled, multicenter study is to evaluate the safety and efficacy of combining a Novartis investigational drug with standard chemotherapy medicines in women with HER2 positive (HER2+) locally advanced or metastatic breast cancer. An "investigational drug" is a drug that is being clinically tested and is not approved for sale or use in the United States by the Food and Drug Administration (FDA), for the indication in which it is being studied.

HER2 Advanced or Metastatic Breast Cancer Trial - W2301

The purpose of this randomized, phase III, double-blind, placebo-controlled multicenter study is to evaluate if adding a Novartis investigational drug to an existing combination therapy offers a more positive “progression-free” result in pretreated women with HER2/Neu Over-Expressing Locally Advanced or Metastatic Breast Cancer. An "investigational drug" is a drug that is being clinically tested and is not approved for sale or use in the United States by the Food and Drug Administration (FDA), for the indication in which it is being studied.